Immunology and the diagnosis of lupus nephritis

Lupus

Volumn 18, Issue 4, 2009, Pages 287-290

  Enghard, Philipp ^a   Riemekasten, G ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD20 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CXCL16 CHEMOKINE; DOUBLE STRANDED DNA ANTIBODY; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PADGEM PROTEIN; SECONDARY LYMPHOID TISSUE CHEMOKINE; TRANSFORMING GROWTH FACTOR BETA3; TUMOR NECROSIS FACTOR RECEPTOR 1; VASCULAR CELL ADHESION MOLECULE 1;

B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE MARKER; EDITORIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE COUNT; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SYSTEMIC LUPUS ERYTHEMATOSUS; URINALYSIS; URINE SEDIMENT;

ANIMALS; BIOLOGICAL MARKERS; CHEMOKINES; CYTOKINES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS;

EID: 62749200438     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203308099632     Document Type: Editorial

References (24)

1. Moore RA, Derry S. Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis. Arthritis Res Ther 2006; 8: R182.
2. Ginzler EM, DooleyMA, Aranow C, et al. Mycophenolatemofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219-2228.
3. Esdaile JM, Joseph L, Abrahamowicz M, Li Y, Danoff D, Clarke AE. Routine immunologic tests in systemic lupus erythematosus: Is there a need for more studies. J Rheumatol 1996; 23: 1891-1896.
4. Rovin BH, Birmingham DJ, Nagaraja HN, Yu CY, Hebert LA. Biomarker discovery in human SLE nephritis. Bull NYU Hosp Jt Dis 2007; 65: 187-193.
5. Potlukova E, Kralikova P. Complement component c1q and anti-c1q antibodies in theory and in clinical practice. Scand J Immunol 2008; 67: 423-430.
6. Jacobi AM, Odendahl M, Reiter K, et al. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2003; 48: 1332-1342.
7. Biesen R, Demir C, Barkhudarova F, et al. Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus. Arthritis Rheum 2008; 58: 136-1145.
8. Brentjens JR, Sepulveda M, Baliah T, et al. Interstitial immune complex nephritis in patients with systemic lupus erythematosus. Kidney Int 1975; 7: 342-350.
9. Jeruc J, Jurcic V, Vizjak A, et al. Tubulo-interstitial involvement in lupus nephritis with emphasis on pathogenesis. Wien Klin Wochenschr 2000; 112: 702-706.
10. Perez de Lema G, Maier H, et al. Chemokine expression precedes inflammatory cell infiltration and chemokine receptor and cytokine expression during the initiation of murine lupus nephritis. J Am Soc Nephrol 2001; 12: 1369-1382.
11. Avihingsanon Y, Phumesin P, Benjachat T, et al.Measurement of urinary chemokine and growth factor messenger RNAs: A noninvasive monitoring in lupus nephritis. Kidney Int 2006; 69: 747-753.
12. Chan RW, Lai FM, Li EK, et al. Expression of chemokine and fibrosing factor messenger RNA in the urinary sediment of patients with lupus nephritis. Arthritis Rheum 2004; 50: 2882-2890.
13. Rovin BH, Song H, Birmingham DJ, Hebert LA, Yu CY, Nagaraja HN. Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J Am Soc Nephrol 2005; 16: 467-473.
14. Li Y, Tucci M, Narain S, et al. Urinary biomarkers in lupus nephritis. Autoimmun Rev 2006; 5: 383-388.
15. Schwartz N, Su L, Burkly LC, et al. Urinary TWEAK and the activity of lupus nephritis. J Autoimmun 2006; 27: 242-250.
16. Chan RW, Tam LS, Li EK, et al. Inflammatory cytokine gene expression in the urinary sediment of patients with lupus nephritis. Arthritis Rheum 2003; 48: 1326-1331.
17. Chan RW, Lai FM, Li EK, et al. Urinary mononuclear cell and disease activity of systemic lupus erythematosus. Lupus 2006; 15: 262-267.
18. Pitashny M, Schwartz N, Qing X, et al. Urinary lipocalin-2 is associated with renal disease activity in human lupus nephritis. Arthritis Rheum 2007; 56: 1894-1903.
19. Wu T, Xie C,Wang HW, et al. Elevated urinary VCAM-1, P-selectin, soluble TNF receptor-1, and CXC chemokine ligand 16 in multiple murine lupus strains and human lupus nephritis. J Immunol 2007; 179: 7166-7175.
20. Noris M, Bernasconi S, Casiraghi F, et al.Monocyte chemoattractant protein-1 is excreted in excessive amounts in the urine of patients with lupus nephritis. Lab Invest 1995; 73: 804-809.
21. Wada T, Yokoyama H, Su SB, et al. Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis. Kidney Int 1996; 49: 761-767.
22. Tesch GH, Maifert S, Schwarting A, Rollins BJ, Kelley VR. Monocyte chemoattractant protein 1-dependent leukocytic infiltrates are responsible for autoimmune disease in MRL-Fas(lpr) mice. J Exp Med 1999; 190: 1813-1824.
23. Enghard P, Humrich JY, Rudolph B, et al. CXCR3+CD4+ T cells are enriched in inflamed kidneys and urine and provide a new biomarker for acute nephritis flares in SLE patients. Arthritis Rheum 2009; 60: 199-206.
24. Segerer S, Banas B, Wornle M, et al. CXCR3 is involved in tubulointerstitial injury in human glomerulonephritis. Am J Pathol 2004; 164: 635-649.